[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530607":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":7,"responsibleParty":18,"collaborators":7,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":7,"acronym":7,"eligibilityCriteria":25,"healthyVolunteers":22,"sex":7,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":26,"phases":7,"briefSummary":27,"conditions":28,"keywords":7,"overallStatus":30,"whyStopped":7,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":35,"locationsCount":7},{"fullName":5,"class":6},"Calico Life Sciences LLC","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","DRUG: ABBV-CLS-484",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"ABBVIE CALL CENTER","CONTACT","847.283.8955","abbvieclinicaltrials@abbvie.com",{"type":19,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100530607","expanded-access-to-abbv-cls-484-100530607",false,"NCT06188975","Expanded Access to ABBV-CLS-484","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.",[29],"Advanced Solid Tumor Cancer","AVAILABLE","2023-12-18",{"date":33,"type":34},"2024-01-03","ACTUAL",{"name":5,"class":6}]